Atyr PHARMA (NASDAQ:ATYR) Posts Earnings Results, Beats Expectations By $0.05 EPS

Atyr PHARMA (NASDAQ:ATYR) issued its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05, Zacks reports.

Atyr PHARMA Price Performance

Shares of NASDAQ ATYR opened at $3.99 on Friday. Atyr PHARMA has a twelve month low of $1.42 and a twelve month high of $4.66. The firm has a fifty day simple moving average of $3.65 and a 200 day simple moving average of $3.04. The company has a market capitalization of $334.93 million, a PE ratio of -4.24 and a beta of 0.98. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ATYR shares. Leerink Partnrs raised shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating for the company. Leerink Partners started coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.